Kiniksa Pharmaceuticals International, plc KNSA Collaboration Expenses
Collaboration Expenses at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept knsa:CollaborationExpenses.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's collaboration expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's collaboration expenses?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported collaboration expenses of $75.58M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's collaboration expenses changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's collaboration expenses increased by 72.6% year-over-year, from $43.79M to $75.58M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's collaboration expenses?
- Over 3 years (2022 to 2025), Kiniksa Pharmaceuticals International, plc's collaboration expenses has grown at a 112.1% compound annual growth rate (CAGR), from $24.07M to $229.55M.
- What does collaboration expenses mean?
- Represents costs incurred through strategic partnerships, licensing agreements, or joint development efforts with other entities. These expenses reflect the financial commitment to shared research, development, or commercialization activities essential for advancing product pipelines. Monitoring these costs helps investors assess the company's reliance on external partners and the efficiency of its collaborative business model.